Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02020707 · ClinicalTrials.gov registry record · Phase 1
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT02020707: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02020707 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02020707, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow tumor growth by blocking the growth of new blood vessels necessary for tumor growth. Giving nab paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Nab-paclitaxel
- BIOLOGICAL Bevacizumab
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-02-24 |
| Est. Completion | 2024-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02020707
The ClinicalTrials.gov registry entry for NCT02020707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02020707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02020707 about?
NCT02020707 is a clinical study titled "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers". This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as...
What is the current status of trial NCT02020707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2014-02-24. Estimated completion is 2024-07-18.
What interventions are being tested in trial NCT02020707?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nab-paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02020707?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.